Table 1.
Scenarios | Case–crossover | Self-controlled case series | ||||||
---|---|---|---|---|---|---|---|---|
Log estimatea | Bias | MSE | OR | Log estimatea | Bias | MSE | IR | |
Base case (no violation of assumptions) | 0.70 | 0.01 | 0.04 | 2.02 | 0.70 | <0.01 | 0.01 | 2.01 |
Time-varying confounder (prevalence 40%) | 0.82 | 0.12 | 0.06 | 2.27 | 0.80 | 0.11 | 0.02 | 2.22 |
Time-varying confounder (prevalence 80%) | 0.91 | 0.22 | 0.09 | 2.49 | 0.90 | 0.21 | 0.05 | 2.46 |
Time trend (linear increase) in precipitant drug exposure prevalence | 0.94 | 0.25 | 0.10 | 2.56 | 0.69 | −0.01 | 0.01 | 1.98 |
90-day precipitant | 0.70 | 0.01 | 0.02 | 2.02 | 0.70 | <0.01 | <0.01 | 2.00 |
Precipitant drug with persistent useb | 1.05 | 0.36 | 0.15 | 2.85 | 0.69 | <0.01 | 0.01 | 1.99 |
Object drug discontinuation (10%) | 0.71 | 0.01 | 0.04 | 2.03 | 0.70 | 0.01 | 0.01 | 2.02 |
Object drug discontinuation (50%) | 0.71 | 0.01 | 0.05 | 2.03 | 0.73 | 0.04 | 0.02 | 2.09 |
Object drug discontinuation (90%) | 0.71 | 0.01 | 0.04 | 2.03 | 0.80 | 0.10 | 0.03 | 2.22 |
True value is 0.69 (OR of 2.0).
Among patients exposed to the precipitant drug, 70% were exposed for 30 days and 30% stayed exposed through the end of the study (persistent use). Bias calculated as the mean difference between the log estimate and the true value (averaged across 1,000 iterations); MSE – mean squared error; OR – odds ratio; IR – incidence ratio. Both OR and IR are calculated as exponential of the mean log estimate.